Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06954246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Minghui Pharmaceutical (Hangzhou) Ltd to Qilu Pharmaceutical Co., Ltd. Trial status: Not Yet Recruiting to Recruiting · Study sites: 0 to 1 · Start date changed from estimate of May 2025 to Jun 4, 2025v2 Show 3 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2025 to Jun 4, 2025
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Trial Details
NCT Number NCT06954246
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov